Background & Aims The evolving epidemiologic patterns of inflammatory bowel disease
(IBD) throughout the world, in conjunction with advances in therapeutic treatments, may …

Background With the introduction of novel therapies for inflammatory bowel diseases
(IBD),'treat‐to‐target'strategies are increasingly discussed to improve short‐and long‐term …

Background Management strategies and clinical outcomes vary substantially in patients
newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic …

Crohn's disease (CD) is a chronic immune‐mediated inflammatory condition which can
negatively impact a patient's quality of life. The traditional management strategy for CD has …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract that might lead
to progressive bowel damage and disability. The exact cause of Crohn's disease is …

Background Visceral adipose tissue (VAT) is involved in the pathogenesis of Crohn's
disease (CD). However, data describing its effects on CD progression remain scarce. We …

Abstract Background and Aims Inflammatory bowel disease (IBD) can lead to long-term
complications that significantly impact patients' quality of life and healthcare resource …

The number of available biological therapies have doubled over the last 10 years and the
arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the …

Aim Inflammatory bowel disease (IBD) exhibited a global increase in incidence over the past
decade. Understanding global burden of IBD can offer valuable insights for shaping future …

Summary Background 5‐aminosalicylates (5‐ASA) are widely used in Crohn's disease (CD)
despite guidelines advising otherwise. We aimed to assess in nationwide study the …